Billionaire investors Warren Buffett, George Soros, and Carl Icahn recently made these big bets.
The design software king hasn’t won over pundits, but there are a few reasons investors should take a good, hard look.
Our team of contributors think that Wall Street has adopted an incorrect view of these three companies.
The development-stage biotech may not have any earnings, but it's producing plenty of data to keep investors interested.
The biotech calendar is already chock-full of major catalysts in 2017. Here's a look at seven stocks that investors will definitely want to keep an eye on next year.
This small data-center chipmaker plans to adopt TSMC's 7-nanometer manufacturing technology.
We talk value investing in tech to follow up our P/E episode on growth investing. Analyst John Rotonti explains some key metrics and discusses a few companies he really likes in the tech space.
Both stocks suffered downgrades this morning, but the damage doesn't end there.
Investors were less than impressed with the software king’s latest earnings, and that translates to a great opportunity.
Of course a stock buyback doesn't look good to Wall Street. Their investing time horizon is too different from yours or mine.